Dr. Agarwal's Health Care Limited has submitted its mandatory quarterly compliance certificate under SEBI Regulation 74(5) for the quarter ended March 31, 2026. The filing confirms the company's adherence to regulatory requirements regarding securities dematerialization and rematerialization activities during the period.

Regulatory Compliance Filing

The certificate was submitted to both BSE Limited and National Stock Exchange of India Limited on April 06, 2026. The document was signed by Thanikainathan Arumugam, Company Secretary and Compliance Officer of Dr. Agarwal's Health Care Limited.

Registrar Confirmation

KFin Technologies Limited, serving as the Registrar and Share Transfer Agent for Dr. Agarwal's Health Care Limited, issued the confirmation certificate dated April 01, 2026. The certificate was signed by Ganesh Chandra Patro, Deputy Vice President at KFin Technologies Limited.

The registrar certified that details of securities dematerialized and rematerialized during the quarter ended March 31, 2026 have been furnished to all stock exchanges where the company's shares are listed, as required under SEBI (Depositories and Participants) Regulations 2018.

Stock Exchange Details

The compliance certificate was submitted to both major Indian stock exchanges where the company's shares are traded:

Company Information

Dr. Agarwal's Health Care Limited operates from its registered office located at 6th Floor, Menon Eternity, 1st Main Road, Austin Nagar, Alwarpet, Chennai - 600 018. The company maintains its regulatory compliance through systematic filing of mandatory certificates and disclosures as required by SEBI regulations.

The quarterly certificate under Regulation 74(5) is a mandatory compliance requirement that ensures transparency in the dematerialization and rematerialization process of securities, providing stakeholders with regular updates on share transfer activities.

Dr. Agarwal's Health Care has officially announced the cessation of Idearx Services Private Limited as an associate company, following the termination of their shareholders' agreement effective March 30, 2026.

Regulatory Disclosure Details

The company filed a regulatory disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, confirming the formal end of its associate relationship with Idearx Services. This disclosure follows an earlier announcement made on February 03, 2026, regarding proposed amendments to the shareholders' agreement.

Agreement Amendment Impact

Pursuant to amendments in both the shareholders' agreement and Idearx's Articles of Association, Dr. Agarwal's Health Care's rights under the original shareholders' agreement have been terminated. The healthcare services provider confirmed that Idearx Services no longer qualifies as an 'Associate' under regulatory definitions.

Continuing Shareholder Rights

Despite the termination of associate status, Dr. Agarwal's Health Care will continue to hold 14.54% of Idearx Services' total equity share capital. The company emphasized that all standard shareholder rights under the Companies Act, 2013, and other applicable laws remain intact.

Strategic Restructuring

This corporate action represents a strategic restructuring move by Dr. Agarwal's Health Care, transitioning from an associate relationship to a standard equity investment position. The measured approach allows the company to maintain financial interest while stepping back from operational collaboration and governance responsibilities associated with associate status.